HomeCompareIRBT vs PFE

IRBT vs PFE: Dividend Comparison 2026

IRBT yields 3703.70% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IRBT wins by $3419432698355.09M in total portfolio value
10 years
IRBT
IRBT
● Live price
3703.70%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3419432698355.14M
Annual income
$3,246,975,791,785,894,400.00
Full IRBT calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — IRBT vs PFE

📍 IRBT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIRBTPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IRBT + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IRBT pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IRBT
Annual income on $10K today (after 15% tax)
$314,814.81/yr
After 10yr DRIP, annual income (after tax)
$2,759,929,423,018,010,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, IRBT beats the other by $2,759,929,423,017,987,600.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IRBT + PFE for your $10,000?

IRBT: 50%PFE: 50%
100% PFE50/50100% IRBT
Portfolio after 10yr
$1709716349177.59M
Annual income
$1,623,487,895,892,960,300.00/yr
Blended yield
94.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

IRBT
Analyst Ratings
8
Buy
14
Hold
2
Sell
Consensus: Hold
Price Target
$65.00
+120270.4% upside vs current
Range: $45.00 — $85.00
Altman Z
-1.9
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IRBT buys
0
PFE buys
0
No recent congressional trades found for IRBT or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIRBTPFE
Forward yield3703.70%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$3419432698355.14M$49.6K
Annual income after 10y$3,246,975,791,785,894,400.00$26,258.71
Total dividends collected$3407630335185.05M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold
Analyst price target$65.00$27.50

Year-by-year: IRBT vs PFE ($10,000, DRIP)

YearIRBT PortfolioIRBT Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$381,070$370,370.37$9,153$693.39+$371.9KIRBT
2$13,598,135$13,190,390.11$8,593$849.25+$13.59MIRBT
3$454,444,009$439,894,003.67$8,336$1,066.78+$454.44MIRBT
4$14,225,576,546$13,739,321,457.33$8,437$1,384.80+$14225.57MIRBT
5$417,170,412,680$401,949,045,774.95$9,013$1,875.40+$417170.40MIRBT
6$11,462,547,850,090$11,016,175,508,522.75$10,306$2,680.72+$11462547.84MIRBT
7$295,153,060,460,047$282,888,134,260,450.30$12,820$4,101.38+$295153060.45MIRBT
8$7,123,461,634,615,992$6,807,647,859,923,741.00$17,673$6,826.70+$7123461634.60MIRBT
9$161,174,679,036,678,200$153,552,575,087,639,100.00$27,543$12,591.86+$161174679036.65MIRBT
10$3,419,432,698,355,140,000$3,246,975,791,785,894,400.00$49,560$26,258.71+$3419432698355.09MIRBT

IRBT vs PFE: Complete Analysis 2026

IRBTStock

iRobot Corporation designs, builds, and sells robots and home innovation products in the United States, Europe, the Middle East, Africa, Japan, and internationally. The company offers floor care products, including Roomba floor vacuuming robots; Roomba accessories and consumables, such as the Clean Base Automatic Dirt Disposal, replacement dirt disposal bags for the Clean Base, filters, brushes, and batteries; Braava family of automatic floor mopping robots; and Braava accessories and consumables, which include cleaning solution, washable and disposable mopping pads, replacement tanks, and batteries, as well as subscription services. It also provides H1 Handheld Vacuum, a portable vacuum; H1 Handheld Vacuum accessories comprising filters, chargers, batteries, and an extension kit that converts the H1 Handheld Vacuum into a stick vacuum; air purifiers under the Aeris brand; Root robots to help children learn how to code; and Create 2, a mobile robot platform that offers an opportunity for educators, developers, and high-school and college students to program behaviors, sounds, movements, and add additional electronics, as well as sells filters and fabric covers. The company sells its products through chain stores and other national retailers, distributors, and resellers, as well as through its website and app, and e-commerce websites. iRobot Corporation was incorporated in 1990 and is headquartered in Bedford, Massachusetts.

Full IRBT Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this IRBT vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IRBT vs SCHDIRBT vs JEPIIRBT vs OIRBT vs KOIRBT vs MAINIRBT vs JNJIRBT vs MRKIRBT vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.